Application of the PKCYP Test to Predict Caffeine Clearance Mediated by CYP1A2 in a Rat Acute Liver Injury Model

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 5, 2003, Pages 296-302

  Kose, Noriko ^a   Kizu, Junko ^a   Miyazaki, Norio ^a   Isawa, Minae ^b   Nakashima, Emi ^b   Takanaka, Akira ^c   Iwasaki, Kazuhide ^d  

^a Department of Practical Pharmacy ^*  (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Org Pharmaceutical Safety and Res   (Japan)

^d PFIZER INC   (United States)

Author keywords

acetanilide; caffeine; carbon tetrachloride treated; CYP1A2; PKCYP test

Indexed keywords

EID: 85024454329     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.296     Document Type: Article

References (20)

1. Ingelman-Sundberg, M.: Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology, 181-182: 447-452 (2002).
2. Tirona, R. G. and Kim, R. B.X Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv. Drug Deliv. Rev., S4: 1343-1352 (2002).
3. Brinkmann, U. and Eichelbaum, M.: Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics, I: 59-64 (2001).
4. Ma, M. K., Woo, M. H. and McLeod, H. L.: Genetic basis of drug metabolism. Am. J. Health. Syst. Pharm., 21: 2061-2069 (2002).
5. Streetman, D. S., Bertino, J. S. Jr. and Nafziger, A. N.: Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics, 10: 187-216 (2000).
6. Wrighton, S. A., Vandenbranden, M., Stevens, J. C., Shipley, L. A., Ring, B. J., Rettie, A. E. and Cashman, J. R.: In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev., 2S: 453-484 (1993).
7. Houston, J. B.: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol., 47: 1469-1479 (1994).
8. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A. and Sugiyama, Y.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., 73: 147-171 (1997).
9. Obach, R. S.: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 27: 1350-1359 (1999).
10. Matsunaga, N., Hattori, K., Iizasa, H., Fukuhara, M., Takanaka, A. and Nakashima, E.: A simplified diagnostic approach for estimating in vivo hepatic drug clearance; its preliminary application for the drug caffeine, using CYP1A probe in a rat model. Jpn. J. Hosp. Pharm., 26: 492-504 (2000).
11. Matsunaga, N., Hattori, K., Iizasa, H., Kizu, J., Takanaka, A. and Nakashima, E.: Application of the PKCYP-test in cases of altered CYP1A2 for multiple CYP systems in rat models of disease. Biol. Pharm. Bull., 24: 1037-1043 (2001).
12. Matsunaga, N., Nishijima, T., Hattori, K., Iizasa, H., Yamamoto, K., Kizu, J., Takanaka, A., Morikawa, A. and Nakashima, E.: Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe. Biol. Pharm. Bull., 24: 1305-1310 (2001).
13. Matsunaga, N., Hayashi, M., Yamamoto, K., Nishijima, T., Kizu, J., Nishihara, K., Takanaka, A., Morikawa, A. and Nakashima, E.: Simultaneous assessment of the in vivo amount of CYP1A2 and CYP3A2 by the PKCYP-test using theophylline in rats. Drug Metabol. Pharmacokin., 17: 190-198 (2002).
14. Bastien, M. C., Leblond, F., Pichette, V. and Villeneuve, J. P.: Differential alteration of cytochrome P4S0 isoenzymes in two experimental models of cirrhosis. Can. J. Physiol. Pharmacol., 78: 912-919 (2000).
15. Sun, B., Fukuhara, M. and Takanaka, A.: Characterization of benzo[a]pyrene metabolism and related cytochrome P-4S0 isozymes in Syrian hamster livers. J. Toxicol Environ. Health, 46: 47-55 (1995).
16. Fukuhara, M., Mizokami, K., Sakaguchi, M., Niimura Y., Kato K., Inouye, S. and Takanaka, A.: Aflatoxin B1-specific cytochrome P-4S0 isosyme (P-4S0-AFB) inducible by 3-methylcholanthrene in golden hamsters. Biochem. Pharmacol., 39: 463-469 (1990).
17. Fukuhara, M., Nohmi, T,., Mizokami, K., Sunouchi, M., Ishidate, M. Jr. and Takanaka, A.: Characterization of three forms of cytochrome P-4S0 inducible by 3-methylcholanthrene in Golden hamster livers with special reference to aflatoxin B1 activation. J. Biochem. (Tokyo), 106: 2S3-2S8 (1989).
18. Yamaoka, K., Nakagawa, T. and Uno, T.: Moment analysis for disposition kinetics of several cephalosporin antibiotics in rats. J. Pharm. Pharmacol., 35: 19-22 (1983).
19. Tanaka, E., Ishikawa, A., and Misawa, S.: Changes in the metabolism of three model substrates catalysed by different P4S0 isozyme when administered as a cocktail to the carbon tetrachloride-intoxicated rat. Xenobiotica., 25: 1111-1118 (1995).
20. Nakashima, E., Yokogawa, K., Ichimura, F., Hashimoto, T., Yamana, T. and Tsuji, A.: Effects of fasting on biperiden pharmacokinetics in the rat. J. Pharm. Sci., 76: 10-13 (1987).